Disorders of purine metabolism in human erythrocytes in the state of lead contamination

• Autorzy: Baranowska-Bosiacka I , Hlynczak A.J. , Wiszniewska B. , Marchlewicz M.
• Języki publikacji: EN

Abstrakty

EN

Although many countries now have programs to lower the levels of lead in the environment, human exposure to Pb remains of concern to public health officials worldwide. The mechanisms of lead toxicity are still not fully understood, but recent findings have recognized the significance of the lead-induced impairment of the cell energy metabolism. This review outlines recent hypotheses and evidence on the role of nucleotide purines in erythrocyte metabolism regulation. It also describes the resynthesis and decomposition of purine nucleotides in erythrocytes, lead distribution in blood and its influence on purine conversion pathways and both glycolytic and pentosophosphate pathway enzymes in erythrocytes.

Słowa kluczowe

EN

purine conversion pathway; purine nucleotide; metabolism; man; lead ion; energy metabolism; erythrocyte; contamination

• Wydawca: -
• Czasopismo: Polish Journal of Environmental Studies
• Rocznik: 2004
• Tom: 13
• Numer: 5
• Opis fizyczny: p.467-476,fig.,ref.

Twórcy

autor

Baranowska-Bosiacka I

• University of Szczecin, Felczaka 3a St., 71-412 Szczecin, Poland

autor

Hlynczak A.J.

autor

Wiszniewska B.

autor

Marchlewicz M.

Bibliografia

• 1. COHEN B.E., LEE G., ARISPE N., POLLARD H.B. Cy­clic 3'-5'- adenosine monophosphate binds to annexin I and regulates calcium- dependent membrane aggregation and ion channel activity. FEBS Lett. 377, 444, 1995.
• 2. EDWARDS F.A., ATP Receptors. Curr. Opin. Neurobiol. 4, 347, 1994.
• 3. TRAUT T.W., Physiological concentrations of purines and pyrimidines. Moll. Cell. Biochem. 140, 1, 1994.
• 4. ZYDOWO M., Universal significance of adenylate metabo­lism. Acta Bioch. Pol. 38, 25, 1991.
• 5. ATKINSON D.E., WALTON G.M., Adenosine triphosphate conservation in metabolic regulation. J. Biol. Chem. 242, 3239, 1967.
• 6. DIN Z.B., BROOKS J.M., Use of adenylate energy charge as a physiological indicator in toxicity experiments. Bull. Environ. Contam. Toxicol. 36, 1, 1986.
• 7. ERECINSKA M., WILSON D.F., Regulation of cellular energy metabolism. J. Membrane Biol. 70, 1, 1982.
• 8. BARANOWSKA- BOSIACKA I., HLYNCZAK A.J., Ef­fect of lead ions on rat erythrocyte purine content. Biol. Trace Elem. Research 100, 3, 2004.
• 9. BARANOWSKA-BOSIACKA I., HLYNCZAK A.J., The effect of lead ions on the energy metabolism of human erythrocytes in vitro. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 134, 403, 2003.
• 10. ATAULLAKHANOV F.I., VITVITSKY V.M., What deter­mines the cellular ATP concentration. Biosci. Rep. 22(5-6), 501, 2002.
• 11. JOZWIAK Z., Adenine nucleotide in the regulation of eryth­rocyte structure and metabolism, Post. Hig. Med. Dosw. 39, 116, 1985.
• 12. ATAULLAKHANOV F. I., VITVITSKY V. M., KOMA- ROVA S. V., MOSHAROV E.V., Energy- dependent pro­cesses and adenylate metabolism in human erythrocytes, Biochemistry (Moscow) 61, 197, 1996.
• 13. MARTINOV M.V., PLOTNIKOV A.G., VITVITSKY V.M., ATAULLAKHANOV F.I., Deficiencies of glycolytic enzymes as a possible cause of hemolytic anemia. Bioch. Bioph. Acta 1474, 75, 2000.
• 14. MATHEWS J.J., ERION M.D., EALICK S.E., Structure of human adenosine kinase at 1,5 A resolution, Biochemistry, 37, 15607, 1998.
• 15. PLAGEMANN P.G., Transport and metabolism of adenosine in human erythrocytes: effect of transport inhibitors and regulation by phosphate. J. Cell. Physiol. 128, 491, 1986.
• 16. SAFRANOW K., Phosphoribosyltransferase (APRT) defi­ciency-molecular and clinical aspects of dihydroxyadeninuria. Postepy Hig Med Dosw. 52(1), 89, 1998.
• 17. DABROWSKA A., Red cell pyruvate kinase maybe con­trols of oxygen delivery from erythrocyte, Post. Hig. Med. Dosw. 51, 305, 1997.
• 18. SMOLENSKI R.T., Evaluation of the adenylate pool in rat cardiomyocytes by S-adenosyl-L-methionine, Acta Biochim. Pol. 47(4), 1171, 2000.
• 19. ZEREZ C. R., WONG M. D., LACHANT N.A., TANAKA K.R., Impaired erythrocyte phosphoribosylpyrophosphate formation in hemolytic anemia due to pyruvate kinase defi­ciency. Blood 72, 500, 1988.
• 20. TANAKA K.R., ZEREZ C.R., Red cell enzymopathies of glycolytic pathway. Semin. Hematol. 27,165, 1990.
• 21. SMOLENSKI R., T., FABIANOWSKA-MAJEWSKA K., MONTERO C., DULEY J.A., FAIRBANKS L.D., MAR- LEWSKI M., SIMMONDS H.A., A novel route of ATP synthesis. Bioch. Pharm. 43, 2053, 1992.
• 22. BONTEMPS F., VAN DEN BERHE G. HERS H.G., Path­ways of adenine nucleotide catabolism in erythrocytes. J. Clin. Invest. 77, 824, 1986.
• 23. RAPOPORT I., DRUG I., RAPOPORT S.M., Catabolism of adenine nucleotides in rabbit blood cells. Biom. Biochim. Acta 49, 11, 1990.
• 24. SMOLENSKI R.T., MONTERO C., DULEY J., SIM- MONDS H.A., Effects of adenosine analogues on ATP con­centrations in human erythrocytes. Biochem. Pharmacol. 42, 1767, 1991.
• 25. SMOLENSKI R.T., KOCHAN Z., MCDOUALL R., PAGE C., SEYMOUR A.M.L., YACOUB M.H., Endothelial nu- cleotide catabolism and adenosine production. Cardiovasc. Res. 28, 100, 1994.
• 26. VAN DEN BERGHE G., BONTEMPS F., Adenine nucleotide catabolism in human erythrocytes: pathways and regu­lation. Biom. Biochim. Acta 49, 117, 1990.
• 27. BONTEMPS F., VAN DEN BERHE G., HERS H.G., 5' nucleotidase activities in human erythrocytes: Identification of a purine 5' nucleotidase stimulated by ATP and glycerate 2, 3-bisphosphate. Biochem. J. 250, 687, 1988.
• 28. SKLADANOWSKI A.C., SMOLENSKI R.T., TAVENIER M., DE JONG J.W., YACOUB M.H., SEYMOUR A.M.L., The soluble forms of 5' nucleotidase in rat and human heart. Am. J. Physiol. 270, 1493, 1996.
• 29. VAN DEN BERGHE G., BONTEMPS F., The purine nucleotide cycle and its molecular defects. Prog. Neurobiol. 39, 547, 1992.
• 30. SKLADANOWSKI A.C., NEWBY A.C., Partial purifica­tion and properties of an AMP specific soluble 5' nucleotidase from pigeon heart. Biochem. J. 268, 117, 1990.
• 31. PESI R., BAIOCCHI C., TOZZI M.G., CAMICI M., Synergistic action of ADP and 2,3 - bisphosphoglycerate on the modulation of cytosolic 5' nucleotidase. Biochim. Biophys. Acta 1294, 191, 1996.
• 32. OUWERKERK, N., STEENWEG, M., DE RUIJTER, M., BROUWER, J., VAN BOOM, J.H., LUGTENBURG, J., RAAP, J., One -pot two step enzymatic coupling of pyrimidine base to 2-deoxy-D-ribose-5-phosphate. A new strategy in the synthesis stable isotope labeled deoxynucleosides, J. Org. Chem. 8 (67), 1480, 2002.
• 33. MASHAROW E.V., VITVITSKY V.M., ATAULLAKHA- NOW F.J., Product activation of human erythrocyte AMP deaminase. FEBS Lett, 440, 64, 1998.
• 34. KALETHA K., NOWAK G., Developmental form of human skeletal muscles AMP-deaminase. The kinetics and regula­tory properties of the enzyme. Biochem. J., 249, 255, 1998.
• 35. DEUSSEN A., Formation and salvage of adenosine by mac- rovascular endothelial cells. Am. J. Physiol. 264 (Heart Circ. Physiol 33), 692, 1993.
• 36. SWIECA A., RYBAKOWSKA I., NAGEL- STARC- ZYNOWSKA G., KOSSOWSKA E., KALETHA K., AMP deaminase from human term placenta, Moll. Cell.Biochem. 252 (1-2), 363, 2003.
• 37. SZYDLOWSKA M., NAGEL-STARCZYKOWSKA G., RYBAKOWSKA I., SWIECA A., KALETHA K., Human liver AMP-deaminase- oligomeric forms of the enzyme. Moll. Cell.Biochem. 241 (1-2), 81, 2002.
• 38. KNECHT K., WIESSMULLER K.H., GNAU V., JUNG G., MEYERMANN R., TODD K.G., HAMPRECHT B., AMP deaminase in rat brain: localization in neurons and ependymal. J. Neurosci. Res. 66 (5), 941, 2001.
• 39. TORECILLA A., MARQUES A.F., BUSCALIONI R.D. OLIVEIRA J.M., TEIXEIRA N.A., ATENCIA E.A., GUNTHER SILLERO M.A., SILLERO A., Metabolic fate of AMP, IMP, GMP and XMP in cytosol of rat brain: an experimental and theoretical analysis. J. Neurochem. 76 (5), 1291, 2001.
• 40. ALLEGRINI S. TOZZI M.G., PESI R., CAMICI M., ER­IKSSON S., Structural and functional aspects of cytosolic 5'-nucleotidase (cN-II). 8th Sympozium European Society for the Study of Purine and Pyrimidyne Metabolism in Man (ESSPPMM), Belgium, 25, 2001.
• 41. PESI R., MICHELI V., JACOMELLI G., PERUZZI L., CAMICI M., GARCIA-GIL M., ALLEGRINI S., TOZZI M.G. Cytosolic 5'-nucleotidase hyperactivity in erythro- cytes of Lesch-Nyhan syndrome patients. Neuroreport, 11 (9), 1827, 2000.
• 42. HOSSAIN M.A., YAMATO O., YAMASAKI M., OTSUKA Y., MAEDE Y., Relation between reticulocyte count and characteristics of erythrocyte 5' nucleotidase in dog, cats and humans. J.Vet. Med. Sci. 65 (2), 193, 2003.
• 43. REES D.C., DULEY J.A., MARIANAKI A.M., Pyrimidine 5' nucleotidase deficiency. Br. J. Haematol. 120 (3), 375, 2003.
• 44. BOZZI A., MARTINI F., LEONARDI F., STROM R., Variations of adenine nucleotide levels in normal and patho­logical human erythrocytes exposed to oxidative stress. Biochem. Mol. Biol. Int. 32, 95, 1994.
• 45. GUTIERREZ-JUAREZ R., CASTREJON-SOSA M., MARTINEZ-VALDEZ H., Activating effect of adenosine on rat erythrocyte glycolysis. Int. J. Biochem. 24, 433, 1992.
• 46. KIM D.M., SWARTZ J.R., regeneration of adenosine tri­phosphate from glycolytic intermediates for cell-free protein synthesis. Biotechnol. Bioeng. 74 (4), 309, 2001.
• 47. COSSU A., MICHELI V., JACOMELLI G., CARCASSI A., Kelley-Seegmiller syndrome in patient with complete hypoxanthine- guanine phosphoribosyl transferase deficiency. Clin. Exp. Rheumatol. 20 (6), 851, 2002.
• 48. MICHELI V., GATHOV B.S., ROCCHIGIANI M., JACO­MELLI G., SESTINI S., PERUZZI L., NOTARANTONIO L., CERBONI B., HAYEK G., POMPUCCI G., Biochemi­cal and molecular study of mental retarded patient with partial deficiency of hypoxanthine- guanine phosphoribosyl transferase. Biochim. Biophys. Acta, 1587 (1) 45, 2002.
• 49. MICHELI V, SESTINI S., ROCCHIGIANI M., JACOME­LLI., MANZONI F., PERUZZI L., GATHOF B.S., ZAM- MARCHI E., POMPUCCI G., Hypoxanthine-guanine phosphoribosyl transferase deficiency and erythrocytesynthesis of pyridine coenzymes. Life Sci. 64,(26), 2479, 1999.
• 50. SIMONS T.J.B., Lead transport and binding by human erythrocytes in vitro. Pfugers Arch. 423, 307, 1993.
• 51. SIMONS T.J.B., Passive transport and binding of lead by human red blood cells. J. Physiol. 378, 267, 1986.
• 52. SIMONS T.J.B., Lead - calcium interactions in cellular lead toxicity. Neurotoxicology 14, 97, 1993.
• 53. BELLONI-OLIVI L., ANADATA G., GOLDSTEIN W., BRESSLER J.P., Phosphorylation of membrane proteins in erythrocytes treated with lead. Bioch. J. 315, 401, 1996.
• 54. OLEKSIUK O.B. FININ V.S., SLOBOZHANINA E.I., Changes in the lipid physical state in human erythrocyte membranes subjected lead exposure in vitro. Biofizika, 48, 246, 2003.
• 55. HOLZHUTTER H., JACOBASCH G., BISDORFF A., Mathematical modeling of metabolic pathways affected by enzyme deficiency. A mathematical model of glycolysis in normal and pyruvate kinase -deficient red blood cells. Eur. J. Biochem. 149, 101, 1985.
• 56. PAGLIUCA A., MUFTI G.J., BALDWIN D., LESTA A.N., WALLIS R.M., BELLINGHAM A.J., Lead poisoning: clinical, biochemical and haematological aspects of recent outbreak. J. Clin. Pathol. 43, 277, 1990.
• 57. LAURENCE A., DULEY J.A., SIMONDS H.A., LAYTON M., Characteristic changes in erythrocyte nucleotides in haemolytic anemia with basophilic stippling of differing aetiology. Cell. Moll. Biol. Lett. 4, 406, 1999.
• 58. SKOCZYNSKA A., STROJEK E., GORECKA H., WOJA- KOWSKA A., Serum vasoactine agents in lead target rats. Int. J. Occup. Med. Environm. Health 16, 169, 2003.
• 59. BATRA N., NEHRU B., BANSAL M.P., The effect of zinc supplementation on the effects of lead on the rat testis. Re­productive Toxicol. 12, 535, 1998.
• 60. FOWLER B.A., Biological roles of high affinity metal- binding proteins in mediating cell injury. Comments Toxicol. 3, 27, 1989.
• 61. PACE V., IANNUCCI E., The importance of vitamins in the relation to presence of heavy metals in food. Panminerva Med. 36, 80, 1994.
• 62. FALKE H.E., ZWENNIS W.C.M., Toxicity of lead acetate to female rabbits after chronic subcutaneous administration. Biochemical and clinical effects. Arch. Toxicol. 64, 522, 1990.
• 63. GRABOWSKA M., GUMINSKA M., The effect of lead on lactate formation, ATP level and membrane ATPase ac­tivities in human erythrocytes in vitro. Int. J. Occup. Med. Environ. Health 9, 265, 1996.
• 64. BHATTACHARJEE C.R., DER S., GOSWAMI P. Protec­tive role of ascorbic acid against lead toxicity in blood of albino mice as relevant by metal uptake, lipid profiles, and ultrastructural features of erythrocytes. Bull. Environm. Contam. Toxicol. 70, 1189, 2003.
• 65. MARCHETTI, C., Molecular targets of lead in brain neuro­toxicity. Neurotoxicity Res., 5 (3), 221, 2003.
• 66. DUTKIEWICZ T., Report of the Polish Academy of Sci­ence, Environmental Toxicology Comittee, Bromat. Chem. Toksykol. 21, 4, 1998.
• 67. WHO. Environmental Health Criteria 165. Inorganic lead. Geneva, 1995.
• 68. RUTKOWSKA M., BARANOWSKA-BOSIACKA I., HLYNCZAK A.J., Lead distribution in whole blood, soft tissues and hair of rats. In: GWOREK B., MISIAK M., (Red.). Element cycling in the environment, Institute of Environmental Protection (IEP), Warsaw, 2003.
• 69. SOLTANINEJAD K., KEBRIAEEZADEH A., MINAIEE B., OSTAD S.N., HOSCEINI R., AZIZI E., Biochemical and ultrastructural evidence for toxicity of lead through free radicals in rat brain. Hum. Exp. Toxicol. 22, 417, 2003.
• 70. TANAKA K.R., ZEREZ C.R., Red cells enzymopathies of glycolytic pathway, Semin. Hematol. 27, 165, 1990.
• 71. TOMODA A., LACHANT N.A., NOBLE N.A., Inhibition of the penthose phosphate shut by 2,3-diphosphoglycerate in erythrocyte pyruvate kinase deficiency. Br.J. Hematol. 54, 475, 1983.
• 72. YUN S.W., HOYER S., Effects of low -level lead on glycolytic enzymes and pyruvate dehydrogenase of rat brain in vitro: relevance to sporadic Alzheimer's disease? J. Neural. Transm. 107, 355, 2000.
• 73. LACHANT N.E., TOMODA A., TANAKA K.R., Inhibition of pentose phosphate shut by lead: potential mechanism for hemolysis in lead poisoning. Blood 63, 518, 1984.
• 74. CASPERS M.L., SIEGEL G.J., Inhibition by lead of human erythrocyte (Na+/K+) adenosine triphosphatase associated with binding of 210Pb to membrane fragments. Bioch. Bioph. Acta 600, 27, 1980.
• 75. HIRATA M., YOSHIDA T., MIYAJIMA K., KOSAKA H., TABUCHI T., Correlation between lead in plasma and other indicators of lead exposure among lead-exposed workers. Int. Arch. Occup. Environ. Health 68, 58, 1995.
• 76. REGUNATHAN S., SUNDARESAN R., Pyruvate metabo­lism in the brain of young rats intoxicated with organic and inorganic lead. J. Neurochem. 43, 1346, 1984.
• 77. FUJII S., BEUTLER E. High glucose concentrations par­tially release hexokinase from inhibition by glukose-6-phos- phate. Proc. Natl. Acad. Sci. USA. 82, 1552, 1985.
• 78. LAKOMEK M., NEUBAUER B., VON DE LUHE A., HOCH G., WINKLER H., SCHROTER W. Erythrocyte pyruvate kinase deficiency: Relations of residual enzyme activity, altered regulation of defective enzymes and con­centrations of high-energy phosphates with the severity of clinical manifestation. Eur. J. Haematol. 49, 82, 1992.
• 79. CORY-SLECHTA D.A., WEISS B., COX C., Delayed be­havioral toxicity of lead with increasing exposure concen­tration. Toxicol.Appl. Pharmacol. 71, 342, 1983.
• 80. ZEREZ C. R., WONG M. D., TANAKA K.R., Partial purifica­tion and properties of nicotinamide adenine dinucleotide synthetase from human erythrocytes: evidence that enzyme activity is a sensitive indicator of lead exposure. Blood 75, 1576, 1990.
• 81. ZEREZ C.R., TANAKA K.R., Impaird nicotinamide ad­enine dinucleotide synthesis in pyruvate kinase deficient human erythrocytes. A mechanism for decreased total NAD content and a possible secondary cause of hemolysis. Blood 69, 999, 1987.
• 82. NEWBY A.C. The pigeon heart 5' - nucleotidase respon­sible for ischemia - induced adenosine formation. Biochem. J. 253, 123, 1988.
• 83. SKLADANOWSKI A.C., NEWBY A.C. Partial purification and properties of an AMP - specific soluble 5' nucleotidase from pigeon heart. Biochem. J. 268, 117, 1990.
• 84. ASAHINA T., KASHIWAGI A., NISHIO Y., Impaired ac­tivation of glucose oxidation and NADPH supply in human endothelial cells exposed to H2O2 in high glucose medium. Diabetes 44, 520, 1995.
• 85. CROWE A., MORGAN E., Interactions between tissue uptake of lead and iron in normal and iron - deficient rats during development. Biol. Trace Elem. Research 52, 249, 1996.
• 86. MESTEK O., DEYL Z., MIKSIK I., NOVOTNA J., Accu­mulation of lead tissues after its administration in drinking water to laboratory rats. Physiol. Res. 47, 197, 1998.
• 87. ANTONIO M.T., LERET M.L., Study of the neuro- chemical alterations produced in discrete brain areas by perinatal low- level lead exposure. Life Sci. 67, 635, 2000.
• 88. JEDRYCZKO A., The role of free radicals in lead poison­ing, Med. Pracy 2, 172, 1994.
• 89. KRAUS A., ROTH H.P., KIRCHGESSNER M., Influence of vitamin C, vitamin E and p- carotene on the osmotic fra­gility and the primary antioxidant system of erythrocytes in zinc-deficient rats. Arch. Anim. Nutr. 50, 257, 1997.
• 90. MAGGIRWAR S.B., DHANRAJ D.N., SOMANI S.M., RAMKUMAR V., Adenosine acts as endogenous activator of the cellular antioxidant defense system. Bioch. Biophys. Research Comm. 201, 508, 1994.
• 91. GURER H., OZGUNES H., NEAL R., SPITZ D., ERCAL N., Antioxidant effects of N-acetylcysteine and succimer in red blood cells from lead- exposed rats. Toxicology 128, 181, 1998.
• 92. KNOWLES S., DONALDSON W.E., Dietary lead alters fatty acid composition and membrane peroxidation in chick liver microsomes. Poult. Sci. 75, 1498, 1996.
• 93. DABROWSKA-BOUTA B., STRUZYNSKA L., RAFALOWSKA U., Does lead provoke the peroxidation process in rat brain synaptosomes? Moll. Chem. Neuropa­thology 29, 127, 1996.
• 94. HAYASHI M., YAMAMOTO K., YOSHIMURA M., KISHIMOTO T., SHITARA A., Effects of fasting on distri­bution and excecretion of lead following long-term lead ex­posure in rats. Arch. Environ. Cont. Toxicol. 24, 201, 1993.